Current News

Contact | Print version | PDF version | Send article | RSS feed

Eden Biodesign and the University of Manchester Intellectual Property Limited develop cancer treatment

08 Aug 2007 - Eden Biodesign Ltd, announced that it has been selected by the University of Manchester Intellectual Property Limited (UMIP) to provide a range of services for the development of a novel therapeutic for treatment of macular degeneration and cancer.
 
Professor Paul Bishop, School of Medicine, University of Manchester, who leads the team that discovered the new therapeutic, commented: "We are very pleased for this exiting programme to be further developed by Eden Biodesign. The experience of Eden Biodesign's management team in the development of biologics ensures that our programme will be well positioned for an accelerated clinical development and will increase the value of our programme to industrial partners."
 
Professor Paul Bishop has been awarded a grant from the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA) towards the cost of the project. The project will be executed at the state of the art NBC, operated by Eden Biodesign and funded by NWDA, European Regional Development Fund (ERDF) and Department of Trade and Industry (DTI). "We are pleased that the NBC is able to provide practical help to Professor Paul Bishop and UMIP Ltd for the commercialisation of their discoveries which have the potential to offer both patient benefit and consolidation of the UK's lead in biopharmaceutical development in Europe" said Dr Linda Magee, NWDA Biotechnology Sector Director & Head of Bionow.